Linagliptin

Linagliptin, the active ingredient in Linagliptin, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus and is used as part of a comprehensive diabetes management plan that includes diet and exercise.

GNH USA supplies Linagliptin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is indicated for the treatment of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.

Type 2 diabetes mellitus: improves glycemic control by enhancing insulin secretion and reducing glucagon release in a glucose‑dependent manner.

Adverse reactions reported with linagliptin are generally mild, but serious events can occur and require medical attention.

Common Side Effects: - Nasopharyngitis - Headache - Upper respiratory tract infection - Gastrointestinal discomfort (nausea, abdominal pain)

Serious or Rare Side Effects: - Pancreatitis - Severe hypersensitivity reactions (e.g., angioedema, Stevens‑Johnson syndrome)

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure safe use.

Renal impairment: monitor renal function, although dose adjustment is not required, use with caution. Hepatic disease: use with caution in patients with moderate hepatic impairment. Pregnancy: safety not established; avoid unless benefit outweighs risk. Concomitant insulin or sulfonylureas: increased risk of hypoglycemia; monitor blood glucose. Elderly patients: may be more susceptible to adverse effects; assess periodically. Store at ambient temperature: keep in original container, protect from moisture and light.

Linagliptin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Co‑administration with insulin or sulfonylureas: may cause severe hypoglycemia; avoid combination unless necessary and monitor closely. - Strong P‑gp inhibitors (e.g., itraconazole, verapamil): can increase linagliptin exposure; avoid.

Moderate Interactions (Monitor Closely): - Rifampin or other strong enzyme inducers: may reduce linagliptin plasma levels and diminish glucose‑lowering effect. - Diuretics (e.g., thiazides): may affect renal handling; monitor renal function. - ACE inhibitors or ARBs: no major interaction but monitor blood pressure.